Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | GABRP | O00591 | 2/20 | 0.42 |
| ▸ | GABRD | O14764 | 2/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.42 |
| ▸ | GABRE | P78334 | 2/20 | 0.42 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.42 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.42 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.42 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL979398 | 0.88 | NAPRT (0.47) | KDM4EALDH1A1GABRPGABRDGABRA1 | |
| SCHEMBL29773884 | 0.88 | NAPRT (0.47) | KDM4EALDH1A1GABRPGABRDGABRA1 | |
| SCHEMBL23579265 | 0.80 | GABRP (0.44) | KDM4EALDH1A1GABRPGABRDGABRA1 | |
| SCHEMBL29959206 | 0.80 | GABRP (0.44) | KDM4EALDH1A1GABRPGABRDGABRA1 | |
| SCHEMBL18786940 | 0.80 | KDM4E (0.45) | KDM4EALDH1A1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL13304188 | 0.80 | NNMT (0.43) | KDM4EALDH1A1TDP1NAPRTSIRT6 | |
| SCHEMBL5762975 | 0.80 | MAPK1 (0.40) | KDM4EALDH1A1TDP1NAPRTSIRT6 | |
| SCHEMBL29562604 | 0.80 | NNMT (0.43) | KDM4EALDH1A1TDP1NAPRTSIRT6 | |
| SCHEMBL30567639 | 0.80 | MAPK1 (0.40) | KDM4EALDH1A1TDP1NAPRTSIRT6 | |
| SCHEMBL21306488 | 0.78 | SMN1; SMN2 (0.42) | KDM4EALDH1A1TDP1GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154147-A1 | NOVEL AMINE-SUBSTITUTED PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2025-05-15 | — | — | US | disclosed |
| EP-4463454-A1 | NOVEL AMINE-SUBSTITUTED PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS | Jazz Pharmaceuticals Ireland Limited (IE) | 2024-11-20 | — | — | EP | disclosed |
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | MIRATI THERAPEUTICS INC (US) | 2024-06-27 | — | — | US | disclosed |
| EP-4304720-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2023135260-A1 | NOVEL AMINE-SUBSTITUTED PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS | JAZZ PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-07-20 | — | — | WO | disclosed |
| WO-2022192745-A1 | MTA-COOPERATIVE PRMT5 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-09-15 | — | — | WO | disclosed |
| US-20190152988-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (JP) | 2019-05-23 | — | — | US | disclosed |
| US-20190152988-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (JP) | 2019-05-23 | — | — | US | disclosed |
| US-10112955-B2 | Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2 | EFFECTOR THERAPEUTICS, INC. (US) | 2018-10-30 | — | — | US | disclosed |
| EP-3368530-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | Effector Therapeutics Inc. (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20170121346-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-05-04 | — | — | US | disclosed |
| US-20170121346-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-05-04 | — | — | US | disclosed |
| US-20170121346-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-05-04 | — | — | US | disclosed |
| WO-2017075394-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (US) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017075394-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (US) | 2017-05-04 | — | — | WO | disclosed |
| WO-2011083316-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011083316-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10112955-B2 | Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2 | NEK9, NEK2, NEK3 | KDM4E 2745/4885ALDH1A1 2954/4885TDP1 2009/4885 |
| US-20190152988-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | NEK9, NEK2, NEK3 | KDM4E 2745/4885ALDH1A1 2954/4885TDP1 2009/4885 |
| US-20170121346-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | NEK9, NEK2, NEK3 | KDM4E 2745/4885ALDH1A1 2954/4885TDP1 2009/4885 |
| US-20240208912-A1 | MTA-Cooperative PRMT5 Inhibitors | PRMT1, PRMT5, PRMT6 | KDM4E 644/4885ALDH1A1 3367/4885TDP1 584/4885 |
| US-20250154147-A1 | NOVEL AMINE-SUBSTITUTED PHTHALAZINES AND DERIVATIVES AS SOS1 INHIBITORS | SOS1, SOS2, SOST | KDM4E 3197/4885ALDH1A1 2412/4885TDP1 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.